Pharsight

1. Amyvid patent expiration

Treatment: Pet to estimate amyloid beta neuritic plaque density in adults with cognitive impairment: -evaluation of alzheimer’s disease and other causes of cognitive decline -selection of patients who are indica...

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8506929	AVID RADIOPHARMS INC	Styrylpyridine derivatives and their use for binding and imaging amyloid plaques	Apr, 2027 (1 year, 3 months from now)
US7687052	AVID RADIOPHARMS INC	Styrylpyridine derivatives and their use for binding and imaging amyloid plaques	Apr, 2027 (1 year, 3 months from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Apr 06, 2017

Drugs and Companies using FLORBETAPIR F-18 ingredient

NCE-1 date: 06 April, 2016

Market Authorisation Date: 06 April, 2012

Dosage: SOLUTION

Strength	Dosage	Availability
10-100ML (13.5-51mCi/ML)	SOLUTION	Prescription
10ML (13.5-51mCi/ML)	SOLUTION	Discontinued
10-30ML (13.5-51mCi/ML)	SOLUTION	Discontinued
10-50ML (13.5-51mCi/ML)	SOLUTION	Prescription

AMYVID family patents

2. Exelon patent expiration

Treatment: Treatment of alzheimer's dementia

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US6316023	April, 2014	Final Written Decision	Novartis AG et al.	Noven Pharmaceuticals, Inc. et al.
US6316023	April, 2014	FWD Entered	Novartis AG	Noven Pharmaceuticals, Inc.
US6316023	November, 2014	Final Written Decision	Novartis AG et al.	Mylan Pharmaceuticals Inc. et al.
US6316023	November, 2014	FWD Entered	Novartis AG	Mylan Pharmaceuticals Inc.
US6335031	April, 2014	Final Written Decision	Novartis AG et al.	Noven Pharmaceuticals, Inc. et al.
US6335031	April, 2014	FWD Entered	Novartis AG	Noven Pharmaceuticals, Inc.
US6335031	November, 2014	Final Written Decision	Novartis AG et al.	Mylan Pharmaceuticals Inc. et al.
US6335031	November, 2014	FWD Entered	Novartis AG	Mylan Pharmaceuticals Inc.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6316023	SANDOZ	TTS containing an antioxidant	Jan, 2019 (7 years ago)
US6335031	SANDOZ	TTS containing an antioxidant	Jan, 2019 (7 years ago)
US4948807	SANDOZ	Phenyl carbamates	Aug, 2012 (13 years ago)
US5602176	SANDOZ	Phenyl carbamate	Feb, 2014 (11 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Strength(NS)	Aug 31, 2015
New Patient Population(NPP)	Jun 27, 2016

Drugs and Companies using RIVASTIGMINE ingredient

Market Authorisation Date: 06 July, 2007

Dosage: FILM, EXTENDED RELEASE

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
4.6 mg/24 hr and 9.5 mg/24 hr	27 Apr, 2011	1		08 Jan, 2019	Extinguished
13.3 mg/24 hr	22 Jan, 2013	1	31 Aug, 2015	08 Jan, 2019	Eligible

Strength	Dosage	Availability
9.5MG/24HR	FILM, EXTENDED RELEASE	Prescription
13.3MG/24HR	FILM, EXTENDED RELEASE	Prescription
4.6MG/24HR	FILM, EXTENDED RELEASE	Prescription

EXELON family patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Exelon patent expiration

Treatment: Treatment of alzheimer's dementia

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US4948807	NOVARTIS	Phenyl carbamates	Aug, 2012 (13 years ago)
US5602176	NOVARTIS	Phenyl carbamate	Feb, 2014 (11 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Strength(NS)	Aug 31, 2015
New Patient Population(NPP)	Jun 27, 2016

Drugs and Companies using RIVASTIGMINE TARTRATE ingredient

Market Authorisation Date: 21 April, 2000

Dosage: CAPSULE; SOLUTION

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
1.5 mg, 3 mg, 4.5 mg and 6 mg	21 Apr, 2004	3	22 Oct, 2007	11 Feb, 2014	Eligible
2 mg/mL	05 Nov, 2004	1		11 Feb, 2014	Extinguished

Strength	Dosage	Availability
EQ 1.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE	Discontinued
EQ 3MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE	Discontinued
EQ 4.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE	Discontinued
EQ 6MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE	Discontinued
EQ 2MG BASE/ML	SOLUTION	Discontinued

EXELON family patents

4. Namenda patent expiration

Treatment: Treatment of moderate to severe dementia of the alzheimer's type

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5061703 (Pediatric)	ALLERGAN	Adamantane derivatives in the prevention and treatment of cerebral ischemia	Oct, 2015 (10 years ago)
US5061703	ALLERGAN	Adamantane derivatives in the prevention and treatment of cerebral ischemia	Apr, 2015 (10 years ago)

Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 18 April, 2005

Dosage: SOLUTION

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
5 mg and 10 mg	16 Oct, 2007	14	30 Jan, 2015	11 Apr, 2015	Eligible

Strength	Dosage	Availability
2MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	SOLUTION	Discontinued

NAMENDA family patents

5. Namenda patent expiration

Treatment: Treatment of moderate to severe dementia of the alzheimer's type

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5061703 (Pediatric)	ABBVIE	Adamantane derivatives in the prevention and treatment of cerebral ischemia	Oct, 2015 (10 years ago)
US5061703	ABBVIE	Adamantane derivatives in the prevention and treatment of cerebral ischemia	Apr, 2015 (10 years ago)

Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 October, 2003

Dosage: TABLET

Pharsight

Pharsight

Alzheimer's Disease Therapeutics

1. Amyvid patent expiration

AMYVID family patents

2. Exelon patent expiration

EXELON family patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Exelon patent expiration

EXELON family patents

4. Namenda patent expiration

NAMENDA family patents

5. Namenda patent expiration

NAMENDA family patents

Have Questions?

Pharsight

Pharsight

Alzheimer's Disease Therapeutics

1. Amyvid patent expiration

AMYVID family patents

2. Exelon patent expiration

EXELON family patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years. Get the exclusive patent insights now. Don't be the last to know. Download Report 3. Exelon patent expiration

EXELON family patents

4. Namenda patent expiration

NAMENDA family patents

5. Namenda patent expiration

NAMENDA family patents

Related content

Have Questions?

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Exelon patent expiration